maximum weight loss tirzepatide surmount trials A 72-week trial compared the two leading GLP-1 medications in adults with obesity (no diabetes). The results: ✓ Tirzepatide: 20.2% ✓ Semaglutide: 13.7% weight loss But weight loss isn't the REDEFINE 4 vs SURMOUNT: how

Certain variants may correlate with greater gastric sensitivity or slower baseline emptying rates, though genetic predisposition does not determine exact medication response

These results show that semaglutide may minimize these risk factors, thereby preventing kidney disease in people living with overweight or obesity

Could new long-acting formulations help improve adherence and long-term outcomes for people living with bipolar I disorder

Motor neuropathy occurred in 21% of GM1 recipients compared with 82% of participants receiving placebo (Su 2020)

With this combination, patients can maximize their weight loss, while developing long term, sustainable habits to optimize their health and wellness